De novo AML with mutated RUNX1 have characteristic clinicopathologic features that include male predominance, higher frequency of SRSF2 and ASXL1 mutations, normal karyotype, and absent NPM1 mutations (68). This evidence concerns the gene SRSF2 and acute myeloid leukemia.